{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:10:17Z","timestamp":1782979817112,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["2024A03J1129"],"award-info":[{"award-number":["2024A03J1129"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["2024B03J1335"],"award-info":[{"award-number":["2024B03J1335"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103221"],"award-info":[{"award-number":["82103221"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072714"],"award-info":[{"award-number":["82072714"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2024JJ6728"],"award-info":[{"award-number":["2024JJ6728"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017695","name":"Health Commission of Hunan Province","doi-asserted-by":"publisher","award":["Z2023100"],"award-info":[{"award-number":["Z2023100"]}],"id":[{"id":"10.13039\/100017695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515220211"],"award-info":[{"award-number":["2023A1515220211"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10495-024-02028-2","type":"journal-article","created":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T08:45:10Z","timestamp":1731228310000},"page":"185-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lenvatinib inhibits cholangiocarcinoma progression by targeting the FGF19\/PI3K\/AKT signaling pathway"],"prefix":"10.1007","volume":"30","author":[{"given":"Yingcheng","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenwei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkai","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenliang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changzhen","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,10]]},"reference":[{"key":"2028_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","volume":"71","author":"P Bertuccio","year":"2019","unstructured":"Bertuccio P, Malvezzi M, Carioli G et al (2019) Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol 71:104\u2013114","journal-title":"J Hepatol"},{"key":"2028_CR2","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/archsurg.2012.1962","volume":"147","author":"D Ribero","year":"2012","unstructured":"Ribero D, Pinna AD, Guglielmi A et al (2012) Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients. Archiv Surg 147:1107\u20131113","journal-title":"Archiv Surg"},{"key":"2028_CR3","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1093\/annonc\/mdq650","volume":"22","author":"W Jiang","year":"2011","unstructured":"Jiang W, Zeng ZC, Tang ZY et al (2011) A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score. Ann Oncol 22:1644\u20131652","journal-title":"Ann Oncol"},{"key":"2028_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00280-017-3353-2","volume":"80","author":"BJ Kim","year":"2017","unstructured":"Kim BJ, Hyung J, Yoo C et al (2017) Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. Cancer Chemother Pharmacol 80:209\u2013215","journal-title":"Cancer Chemother Pharmacol"},{"key":"2028_CR5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273\u20131281","journal-title":"N Engl J Med"},{"key":"2028_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/sj.bjc.6605211","volume":"101","author":"JW Valle","year":"2009","unstructured":"Valle JW, Wasan H, Johnson P et al (2009) Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study\u2014the UK ABC-01 study. Br J Cancer 101:621\u2013627","journal-title":"Br J Cancer"},{"key":"2028_CR7","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401:1853\u20131865","journal-title":"Lancet"},{"key":"2028_CR8","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","volume":"25","author":"HA Burris 3rd","year":"2024","unstructured":"Burris HA 3rd, Okusaka T, Vogel A et al (2024) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 25:626\u2013635","journal-title":"Lancet Oncol"},{"issue":"1","key":"2028_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hep.31278","volume":"73","author":"CJ O\u2019Rourke","year":"2021","unstructured":"O\u2019Rourke CJ, Munoz-Garrido P, Andersen JB (2021) Molecular targets in cholangiocarcinoma. Hepatology 73(1):62\u201374","journal-title":"Hepatology"},{"key":"2028_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ccr.2011.01.040","volume":"19","author":"ET Sawey","year":"2011","unstructured":"Sawey ET, Chanrion M, Cai C et al (2011) Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 19:347\u2013358","journal-title":"Cancer Cell"},{"key":"2028_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bbrc.2014.02.050","volume":"446","author":"YF Xu","year":"2014","unstructured":"Xu YF, Yang XQ, Lu XF et al (2014) Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma. Biochem Biophys Res Commun 446:54\u201360","journal-title":"Biochem Biophys Res Commun"},{"key":"2028_CR12","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1074\/jbc.M109.068783","volume":"285","author":"X Wu","year":"2010","unstructured":"Wu X, Ge H, Lemon B et al (2010) FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 285:5165\u20135170","journal-title":"J Biol Chem"},{"key":"2028_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3389\/fcell.2020.00095","volume":"8","author":"Y Liu","year":"2020","unstructured":"Liu Y, Cao M, Cai Y, Li X, Zhao C, Cui R (2020) Dissecting the role of the FGF19-FGFR4 signaling pathway in cancer development and progression. Front Cell Dev Biol 8:95","journal-title":"Front Cell Dev Biol"},{"key":"2028_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","volume":"36","author":"M Javle","year":"2018","unstructured":"Javle M, Lowery M, Shroff RT et al (2018) Phase II study of BGJ398 in patients With FGFR-altered advanced cholangiocarcinoma. J Clin Oncol 36:276\u2013282","journal-title":"J Clin Oncol"},{"key":"2028_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A et al (2020) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 21:671\u2013684","journal-title":"Lancet Oncol"},{"key":"2028_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1200\/JCO.2020.38.15_suppl.108","volume":"38","author":"L Goyal","year":"2020","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A et al (2020) FOENIX-CCA2: a phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements. J Clin Oncol 38:108\u2013108","journal-title":"J Clin Oncol"},{"key":"2028_CR17","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/cas.15719","volume":"114","author":"Z Mei","year":"2023","unstructured":"Mei Z, Gao X, Pan C et al (2023) Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1(+) CD8(+) T cells in HCC via blocking VEGFR2. Cancer Sci 114:1284\u20131296","journal-title":"Cancer Sci"},{"key":"2028_CR18","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1186\/s12885-020-07365-4","volume":"20","author":"M Ueno","year":"2020","unstructured":"Ueno M, Ikeda M, Sasaki T et al (2020) Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results. BMC Cancer 20:1105","journal-title":"BMC Cancer"},{"key":"2028_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.785535","volume":"12","author":"Y Wang","year":"2022","unstructured":"Wang Y, Yang X, Wang D et al (2022) Lenvatinib beyond first-line therapy in patients with advanced biliary tract carcinoma. Front Oncol 12:785535","journal-title":"Front Oncol"},{"key":"2028_CR20","doi-asserted-by":"publisher","first-page":"414","DOI":"10.21037\/hbsn-20-338","volume":"9","author":"J Lin","year":"2020","unstructured":"Lin J, Yang X, Long J et al (2020) Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg Nutr 9:414\u2013424","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2028_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.751391","volume":"11","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Liu X, Wei S et al (2021) Lenvatinib plus PD-1 inhibitors as first-line treatment in patients with unresectable biliary tract cancer: a single-arm, open-label, phase II study. Front Oncol 11:751391","journal-title":"Front Oncol"},{"key":"2028_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01317-7","author":"GM Shi","year":"2023","unstructured":"Shi GM, Huang XY, Wu D et al (2023) Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study. Sig Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-023-01317-7","journal-title":"Sig Transduct Target Ther"},{"key":"2028_CR23","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s10495-024-01982-1","volume":"29","author":"Q Wang","year":"2024","unstructured":"Wang Q, Tan W, Zhang Z et al (2024) FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma. Apoptosis 29:1529","journal-title":"Apoptosis"},{"key":"2028_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jare.2022.03.012","volume":"44","author":"W Tan","year":"2023","unstructured":"Tan W, Zhang K, Chen X et al (2023) GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma. J Adv Res 44:173\u2013183","journal-title":"J Adv Res"},{"key":"2028_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1471-2407-12-56","volume":"12","author":"S Miura","year":"2012","unstructured":"Miura S, Mitsuhashi N, Shimizu H et al (2012) Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer 12:56","journal-title":"BMC Cancer"},{"key":"2028_CR26","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/cas.13169","volume":"108","author":"M Matsuki","year":"2017","unstructured":"Matsuki M, Adachi Y, Ozawa Y et al (2017) Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus. Cancer Sci 108:763\u2013771","journal-title":"Cancer Sci"},{"key":"2028_CR27","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s10637-014-0149-7","volume":"32","author":"F Ewald","year":"2014","unstructured":"Ewald F, N\u00f6rz D, Grottke A, Hofmann BT, Nashan B, J\u00fccker M (2014) Dual inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. Invest New Drugs 32:1144\u20131154","journal-title":"Invest New Drugs"},{"key":"2028_CR28","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","volume":"169","author":"BD Manning","year":"2017","unstructured":"Manning BD, Toker A (2017) AKT\/PKB signaling: navigating the network. Cell 169:381\u2013405","journal-title":"Cell"},{"key":"2028_CR29","first-page":"1","volume":"2024","author":"S Shin","year":"2024","unstructured":"Shin S, Chew NJ, Ghomlaghi M et al (2024) Integrative modeling of signaling network dynamics identifies cell type-selective therapeutic strategies for FGFR4-driven cancers. Cancer Res 2024:1\u201310","journal-title":"Cancer Res"},{"key":"2028_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2019.02.015","volume":"513","author":"T Hoshi","year":"2019","unstructured":"Hoshi T, Watanabe Miyano S, Watanabe H et al (2019) Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades. Biochem Biophys Res Commun 513:1\u20137","journal-title":"Biochem Biophys Res Commun"},{"key":"2028_CR31","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163\u20131173","journal-title":"Lancet"},{"key":"2028_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017832","volume":"98","author":"WX Chen","year":"2019","unstructured":"Chen WX, Li GX, Hu ZN, Zhu P, Zhang BX, Ding ZY (2019) Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: a case report and literature review. Medicine 98:e17832","journal-title":"Medicine"},{"key":"2028_CR33","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/cam4.1517","volume":"7","author":"M Matsuki","year":"2018","unstructured":"Matsuki M, Hoshi T, Yamamoto Y et al (2018) Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med 7:2641\u20132653","journal-title":"Cancer Med"},{"key":"2028_CR34","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/hep.31921","volume":"74","author":"C Yi","year":"2021","unstructured":"Yi C, Chen L, Lin Z et al (2021) Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC. Hepatology 74:2544\u20132560","journal-title":"Hepatology"},{"key":"2028_CR35","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nrc.2017.8","volume":"17","author":"IS Babina","year":"2017","unstructured":"Babina IS, Turner NC (2017) Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer 17:318\u2013332","journal-title":"Nat Rev Cancer"},{"key":"2028_CR36","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/mc.22884","volume":"57","author":"X Zhao","year":"2018","unstructured":"Zhao X, Xu F, Dominguez NP et al (2018) FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression. Mol Carcinog 57:1616\u20131625","journal-title":"Mol Carcinog"},{"key":"2028_CR37","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.7150\/jca.50292","volume":"12","author":"J Ye","year":"2021","unstructured":"Ye J, Qi L, Liang J et al (2021) Lenvatinib induces anticancer activity in gallbladder cancer by targeting AKT. J Cancer 12:3548\u20133557","journal-title":"J Cancer"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-024-02028-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-024-02028-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-024-02028-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T13:13:36Z","timestamp":1738761216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-024-02028-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,10]]},"references-count":37,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2028"],"URL":"https:\/\/doi.org\/10.1007\/s10495-024-02028-2","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,10]]},"assertion":[{"value":"2 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was approved by the Experimental animal ethics committee of Sun Yat-sen University (approval number: SYSU-IACUC-2020-000056).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}